These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 25974088

  • 21. [Expression of enhancer of zeste homolog 2 in esophageal squamous cell carcinoma and its prognostic value in postoperative patients].
    Wang HR, Wang MH, Lian GY, Wu DG.
    Nan Fang Yi Ke Da Xue Xue Bao; 2015 Jan; 35(1):99-102. PubMed ID: 25613619
    [Abstract] [Full Text] [Related]

  • 22. EZH2 expression in invasive lobular carcinoma of the breast.
    Roh S, Park SY, Ko HS, Sohn JS, Cha EJ.
    World J Surg Oncol; 2013 Nov 22; 11():299. PubMed ID: 24266940
    [Abstract] [Full Text] [Related]

  • 23. High immunoexpression of Ki67, EZH2, and SMYD3 in diagnostic prostate biopsies independently predicts outcome in patients with prostate cancer.
    Lobo J, Rodrigues Â, Antunes L, Graça I, Ramalho-Carvalho J, Vieira FQ, Martins AT, Oliveira J, Jerónimo C, Henrique R.
    Urol Oncol; 2018 Apr 22; 36(4):161.e7-161.e17. PubMed ID: 29174711
    [Abstract] [Full Text] [Related]

  • 24. Prognostic value of EZH2 expression and activity in renal cell carcinoma: a prospective study.
    Liu L, Xu Z, Zhong L, Wang H, Jiang S, Long Q, Xu J, Guo J.
    PLoS One; 2013 Apr 22; 8(11):e81484. PubMed ID: 24312307
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. High-grade neuroendocrine carcinomas of the lung highly express enhancer of zeste homolog 2, but carcinoids do not.
    Findeis-Hosey JJ, Huang J, Li F, Yang Q, McMahon LA, Xu H.
    Hum Pathol; 2011 Jun 22; 42(6):867-72. PubMed ID: 21292308
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome.
    Gong Y, Huo L, Liu P, Sneige N, Sun X, Ueno NT, Lucci A, Buchholz TA, Valero V, Cristofanilli M.
    Cancer; 2011 Dec 15; 117(24):5476-84. PubMed ID: 21713757
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Alterations in enhancer of zeste homolog 2, matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression are associated with ex vivo and in vitro bone metastasis in renal cell carcinoma.
    Wang J, Ren Y, Guo X, Cheng H, Ye Y, Qi J, Yang C, You H.
    Mol Med Rep; 2015 May 15; 11(5):3585-92. PubMed ID: 25571919
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Enhancer of zeste homolog 2 (EZH2) promotes tumour cell migration and invasion via epigenetic repression of E-cadherin in renal cell carcinoma.
    Liu L, Xu Z, Zhong L, Wang H, Jiang S, Long Q, Xu J, Guo J.
    BJU Int; 2016 Feb 15; 117(2):351-62. PubMed ID: 24612432
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.